PASITHEA THERAPEUTICS CORP (KTTA)
US70261F2020 - Common Stock
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024
Pasithea Therapeutics just reported results for the first quarter of 2024.
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024....
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments....
Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study (NASDAQ:KTTA)
Pasithea Therapeutics (KTTA) has conducted a 1-for-20 reverse stock split and received FDA clearance for Phase 1 study of its oncology drug PAS-004. Read more here.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19....
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)...
RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With ‘Overweight’ Rating
Roblox stock is rising higher on Wednesday after Wells Fargo initiated coverage of RBLX shares wit a bullish rating and price target.
PLTR Stock: Palantir Renews UniCredit Partnership
Palantir Technologies stock is slipping on Wednesday even with positive news for PLTR investors in the form of a renewed contract.
Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?
ReShape Lifesciences stock is rising with heavy trading of RSLS shares alongside an update from the FDA concerning its weight loss products.
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Pasithea Therapeutics stock is falling on Wednesday after shares of KTTA underwent extreme volatility yesterday on study results.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
Pasithea Therapeutics stock is climbing higher with heavy trading of KTTA shares alongside results from two preclinical trials.
Pasithea stock soars as high as 190% on preclinical data (NASDAQ:KTTA)
Pasithea (KTTA) shares soared as high as 190% after the company released encouraging data from two preclinical studies of its oncology drug candidate PAS-004. Read more here.
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Pasithea Therapeutics adjourns 2023 annual meeting of stockholders....
Pasithea stock jumps 12% on update for anti-tumor drug PAS-004 (KTTA)
Pasithea (KTTA) stock jumped 12% on news that the company hopes to begin clinical testing of its drug PAS-004 in Q1 2024, pending FDA acceptance of its IND. Read more here.
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004...